Precision Medicine Leaders’ Summit 2019 – East
The Precision Medicine Leaders Summit is proud to partner with one of the most prestigious and the oldest medical schools in the United States, The Perelman School of Medicine at the University of Pennsylvania. The UPenn School of Medicine provides the perfect backdrop to continue the discussion on the implementation or Precision Medicine, across not only large research institutions, but community settings where up to 85% of patients currently receive treatment.
Building on the successes of our events in San Diego and Jersey City, we hope you will join us for the most thought-provoking Precision Medicine event in the marketplace. Our speakers cover the panoply of leaders in the healthcare continuum, these include clinicians, industry experts, academics, regulators, payers, genetic counselors, bioinformaticians, and many more who are shaping the way Precision Medicine is implemented into healthcare systems on a global scale.
Join us for panel discussions, keynotes, roundtables, networking, exhibits, and opening reception to hear from thought leaders who are making the promise of Precision Medicine a reality.
TUESDAY JUNE 11th, 2019
Registration & Breakfast Buffet
Welcome and Opening Remarks
David Roth, MD, PhD, Simon Flexner Professor and Chair of Pathology and Laboratory Medicine, Director, Penn Center for Precision Medicine, University of Pennsylvania Perelman School of Medicine
Nigel Russell, Founder & President, The Journal of Precision Medicine and the Precision Medicine Leaders Summits.
Keynote – Stay Tuned – TBD
Immunotherapies and their Impact on Precision Medicine
Advancing Precision Health with Approaches that Leverage Previously Unconnected Biomolecular and Clinical “Big Data”
Moderator: Yves A. Lussier, MD, FACMI, Associate Vice President for Health Sciences and Chief Knowledge Officer
Executive Director, Center for Biomedical Informatics and Biostatistics University of Arizona Health Sciences
Panelists: Jason H. Moore, PhD, FACMI, Edward Rose Professor of Informatics,Director, Institute for Biomedical Informatics,Director, Division of Informatics, Department of Biostatistics, Epidemiology, & Informatics,Senior Associate Dean for Informatics ,The Perelman School of Medicine University of Pennsylvania
The availability of Big Data across multiple dimensions, from electronic health records, lifestyles, environmental factors, genetics, to genomics, presents diverse challenges for existing informatics technology, in terms of computational efficiency, modeling effectiveness, statistical computing, discovery algorithms, and heterogeneous data integration. A growing trend is the creative integration of data collected independently for different purposes often not sharing common identifiers to enable novel analytical inferences unfeasible from smaller datasets. For example, novel toxidromes may be unveiled from jointly analyzing pollution data geospatially across different domains (i.e., air, land, and water) with clinical data. This panel will discuss analytics in the field of translational bioinformatics that strives to bridge the gap between disciplines among statistical genetics, clinical informatics, and bioinformatics as well as previously unconnected datasets (e.g., Emerge, GTEx, GEO, All of Us, UK Biobank, DrugBank), to advance precision health.
Coffee & Networking
Molecular Tumor Boards Impact on Precision Medicine
Update on All of Us Program
Stephanie Devaney, PhD, Deputy Director, All of Us Research Program, NIH
The All of Us Research Program is a key element of the Precision Medicine Initiative (PMI). Through advances in research, technology, and policies that empower patients, the PMI will enable a new era of medicine in which researchers, health care providers, and patients work together to develop individualized care.
PMI launched in fiscal year 2016 when $130 million was allocated to NIH to build a national, large-scale research participant group, called a cohort, and $70 million was allocated to the National Cancer Institute to lead efforts in cancer genomics as part of PMI for Oncology.
1:35 – 2:25pm
Precision Medicine Clinical Trials and Novel Designs: Levering Data, ‘Omics’, AI and Policy
Moderator: Arturo Loaiza Bonilla, MD, MSEd, FACP, Vice Chair, Department of Medical Oncology, CTCA
Panelists: Selin Kurnaz, PhD, CEO – Massive Bio, Richard Schilsky, MD, FACP, FASCO, FSCT, Senior Vice President and Chief Medical Officer, ASCO, Gary Palmer, MD, Chief Medical Officer, Tempus
The paradigm changes from the ‘phenotype-to-genotype’ to the ‘genotype-to-phenotype’ approach has revolutionized R&D and Clinical trials in oncology and other diseases. This panel will discuss the impact of novel approaches to clinical trial design, including the use of technology, biomarker data and the current regulatory landscape which is moving the needle forward in earlier access and approval of promising compounds. The audience will be able to learn further about ‘basket’, ‘umbrella’, ‘seamless’, ‘adaptive’ design trials, synthetic control arms, ‘Just-In-Time (JIT) trials, as will have the opportunity to how different stakeholders are adapting to recent FDA policies and regulations for their R&D and clinical trial matching enrollment.
Biomarkers to Predict Response and Resistance to Targeted and Immunotherapies
Moderator: Nic Dracopoli,
Panelists: Timothy Chan MD, PaineWebber Chair in Cancer Genetics; Director, Immunogenomics and Precision Oncology Platform; Member, Human Oncology & Pathogenesis Program; Vice Chair, Department of Radiation Oncology; Director, Translational Oncology Division, Ilan “Lanny” Kirsch, M.D. Senior Vice President of Translational Medicine, Adaptive Biotechnologies
Dracopoli – Predicting response to targeted and immunotherapies
Kirsch – Immunosequencing in the service of immune-oncology
Chan – Genetic determinants of immunotherapy efficacy and resistance
This session will provide an update on the current use of biomarkers to predict response to targeted and immunotherapies in the treatment of cancer patients. Speakers in the session will discuss latest developments of deep sequencing of the T-Cell receptor to look for clonal T-cell infiltration in tumors as evidence of a prior suppressed immune response, evaluation of individual somatic alterations driving response to targeted signal transduction inhibitors, and to evaluate tumor mutation burden and HLA Class I antigen presentation to predict response to checkpoint inhibitors.
Coffee & Networking
Innovation in Genomic Medicine Implementation
Moderator: Erica Ramos, MS, LCGC President National Society of Genetic Counselors and Director of Business development, Geisinger National Precision Health.
Panelists: Erynn Gordon, MS, LCGC, VP of Clinical Operations, Genome Medical, Tara Schmidlen, MS, CGC, Clinical Investigator/Genetic Counselor, Geisinger Health System
While the technology and knowledge driving precision medicine continue to press ahead, how do we assure real value is realized for the acute setting equitably and at scale – and for populations, in context with fostering healthy communities. What are strategies to bridge the current landscape to a more harmonious future? What are we doing right? What will we regret? What will we laugh about? A panel of experts will have an honest assessment and share their vision for leaders in many facets of the field, from academia to industry to the community.
4:40 – 5:30pm
Women’s Health in Precision Medicine
Moderator: Amy Miller PhD, CEO – Society for Women’s Health Research
Panelists: Katie Johansen Taber, PhD, Director, Clinical Development Myriad Women’s Health, Virginia Miller, MBA, PhD, – Professor, Surgery and Physiology, Director, Women’s Health Research Center, Mayo Clinic
Networking Reception at Penn Museum (China & Egypt Exhibits) – enjoy drinks and hors d’houvres with fellow attendees, speakers and sponsors.
WEDNESDAY JUNE 12th, 2019
Day One Recap
Gene Editing – The Breakthrough Technology
Moderator: Eric Kmiec, PhD, Director, Gene Editing Program,Senior Research Scientist, Center for Translational Cancer Research, Helen F. Graham Cancer Center and Research Institute, Christiana Care Health System
Panelists: Lorenz Mayr, PhD, Chief Technology Officer, GE Healthcare
CRISPR-directed human gene editing, is a form of precision medicine that is considered to be a breakthrough technology. While certainly not alone in this space, transition from bench to bedside requires that these technologies, especially for therapeutic use, are not only reproducible but robust. This line of thinking means that outstanding technological advances made in top laboratories around the world with unlimited resources are viewed as exciting and dramatic science. But, unless these technologies can be carried out within a diverse patient population, they will have little impact on patient care and will not be delivered in an efficient fashion. A robust technology means that just about every location or caregiver can carry out the process and isn’t limited to specific sites around the country that have the highest degree of technological and service expertise.
10:05 – 10:35am
Coffee & Networking
Mind the Gap: Are Mutational Profiles Sufficient for Precision Medicine?
Moderator: John Quakenbush, PhD, Henry Pickering Walcott Professor of Computational Biology and Bioinformatics
Chair, Department of Biostatistics, TH Chan School of Public Health, Harvard University
Much of precision medicine has been built on the idea that we can match patients to appropriate therapies based on their genetic background or that of their disease. But despite the success of targeted therapies and their associated biomarkers, not every patient with or without the “predictive” mutation responds as expected to the associated therapy. This suggests that single biomarkers are not sufficient and argues for more sophisticated, network medicine approaches. This panel will explore the limits of current precision medicine strategies and the ways in which these might be extended to better match patients to the most appropriate therapy.
Transforming healthcare through AI-driven clinical genomic insights to improve patient lives.
Charlene Son Rigby, MBA CBO Fabric Genomics
Precision medicine promises customized patient therapy by maximizing treatment effectiveness and minimizing side effects. Genomics is a critical tool in making precision medicine a reality. With genomic testing becoming more mainstream within the U.S. and worldwide, clinical and hospital laboratories are starting to publish compelling data on its utility. Yet adoption continues to be hampered by cost. Technology advances are critical to lower costs and accelerate adoption. The importance of technology, automation and the role for AI in genomic data interpretation will be discussed along with patient examples including ending her family’s diagnostic odyssey through whole exome testing.
Public Health and Precision Medicine Working in Harmony
Moderator: David B Nash, MD, MBA, Dean Jefferson College of Population Health, Dr. Raymond C. & Doris N. Grandon Professor of Health Policy, Thomas Jefferson University
Diagnostic and Clinical Data Integration: A Framework for Improving Quality of Care
Despite the advances in health care data interoperability, multimodal patient data remains trapped in disparate data systems creating access problems for clinicians and complicating information sharing between multidisciplinary teams. The promise of precision medicine is to improve the quality of patient care by leveraging diagnostic data to drive clinical treatment decisions that result in better patient outcomes. Breaking down data silos allows organizations to design, track and document new quality metrics for the purpose of continuously improving quality of care for clinicians as well as enabling the development of clinical evidence necessary to establish medical necessity, actionability and clinical utility for diagnostics.
COFFEE & NETWORKING
The Role of AI, Blockchain & Machine Learning in PM
Severence MacLaughlin, PhD, Vice President Artificial Intelligence and Data Sciences, Capgemini Invent, David Houlding MSc CISSP CIPP, Principal Health Care Lead, Cloud & AI, Microsoft
Expanding Precision Medicine – The Path to Higher-Value Care
Proteomics in PM
Richard Schilsky, MD, FACP, FASCO, FSCT
Senior Vice President and Chief Medical Officer (CMO) of ASCO
Dr. Schilsky is the Senior Vice President and Chief Medical Officer (CMO) of ASCO. He assumed this newly created position with the Society in February of 2013. Formerly the Chief of Hematology/Oncology in the Department of Medicine and Deputy Director of the University of Chicago Comprehensive Cancer Center, he is a highly respected leader in the field of clinical oncology. He specializes in new drug development and treatment of gastrointestinal cancers. Dr. Schilsky is a Past President of ASCO, having served in the role during 2008-2009, and also a Past Chair of one of the National Cancer Institute’s Cooperative Groups, Cancer and Leukemia Group B (CALGB).
Dr. Schilsky’s impressive experience and many accomplishments in both clinical medicine and clinical research reflect his deep passion for cancer medicine. Having served in prior leadership positions within ASCO, Dr. Schilsky has an in-depth understanding of the current trends and issues affecting oncology clinical practice. He has spent the majority of his career at the University of Chicago where he joined the faculty in 1984, subsequently rising to the rank of Professor of Medicine and serving in many roles, including Associate Dean for Clinical Research in the Biological Sciences Division and Director of the University of Chicago Cancer Research Center.
From 1995 to 2010, Dr. Schilsky served as chair of the Cancer and Leukemia Group B, a national cooperative clinical research group funded by the National Cancer Institute (NCI). He has extensive experience working with both the NCI and the Food and Drug Administration (FDA) having served as a member and chair of the NCI Board of Scientific Advisors, as a member of the NCI Clinical and Translational Research Committee, and as a member and chair of the Oncologic Drugs Advisory Committee of the FDA. Dr. Schilsky has served on the editorial boards of many cancer journals, including the Journal of Clinical Oncology. Most recently, he served as an Associate Editor of the Journal of the National Cancer Institute and Senior Associate Editor of Molecular Oncology, among other journals.
Early in his career, he worked in the Clinical Pharmacology Branch of the Division of Cancer Treatment at the NCI and was an Assistant Professor in the Department of Internal Medicine, Division of Hematology and Oncology at the University of Missouri-Columbia School of Medicine. He was also the head of the hematology/medical oncology unit at the Harry S. Truman Veterans’ Administration Hospital in Columbia, Missouri.
Erynn Gordon, MS, LCGC
VP of Clinical Operations, Genome Medical
Erynn is a board-certified genetic counselor with expertise in clinical care, research and laboratory genetics. A leader in the genetic counseling community, Erynn has served as President of the American Board of Genetic Counseling and on the National Society of Genetic Counselors Board of Directors. Prior to joining Genome Medical, Erynn was the first genetic counselor at 23andMe, serving as Director of Clinical Affairs. She previously managed a precision medicine study at at the Coriell Institute for Medical Research and held clinical roles at University of Maryland School of Medicine and Children’s National Medical Center.
Katie Johansen Taber, PhD.
Director, Clinical Development, Myriad Women’s Health
Katherine (Katie) Johansen Taber, PhD is the Director of Clinical Development at the newly formed Myriad Women’s Health (formerly Counsyl). Her focus is on strategizing, designing, conducting, and publishing studies demonstrating the utility of prenatal and hereditary cancer risk screening in the women’s health setting. She additionally oversees a team working to maintain the clinical excellence of Myriad Women’s Health’s products and services. Before joining Counsyl/Myriad Women’s Health, she spent more than a decade at the American Medical Association, with a primary focus on educating physicians about the clinical implementation of genomics and precision medicine, and on identifying and managing genomics and precision medicine policy issues affecting health care providers. She has held numerous positions on advisory committees and boards of organizations working to improve clinical adoption of genomic technology, including a current appointment on the National Academy of Sciences, Engineering, and Medicine Roundtable on Genomics and Precision Health. Katie earned her PhD in Molecular, Cell, and Developmental Biology at the University of California, Los Angeles, and conducted post-doctoral research at the USDA. She has held teaching appointments at UCLA, California State Polytechnic University, University of Idaho, and Columbia College Chicago.
John Quackenbush, PhD
Henry Pickering Walcott Professor of Computational Biology and Bioinformatics
Chair, Department of Biostatistics, Harvard University T.H. Chan School of Public Health
John Quackenbush is Professor of Computational Biology and Bioinformatics and Chair of the Department of Biostatistics at the Harvard TH Chan School of Public Health and Professor of Biostatistics and Computational Biology at the Dana-Farber Cancer Institute. John’s PhD was in Theoretical Physics, in 1992 he received a fellowship from the National Institutes of Health to work on the Human Genome Project, which led him from the Salk Institute to Stanford University to The Institute for Genomic Research (TIGR) before moving to Harvard in 2005. John’s research uses massive data from DNA sequencing and other assays to model functional networks in human cells. By comparing networks between groups of individuals, he has found new drug targets, explored chemotherapy resistance, and investigated differences between the sexes. He has made pioneering discoveries about how the genetic variants work together to determine our traits. John has published more than 280 papers; his work has been cited more than 65,000 times. He has received numerous awards for his work, including recognition in 2013 as a White House Open Science Champion of Change. He is also the co-founder of Genospace, a precision medicine software company that was purchased by the Hospital Corporation of America in 2017.
Jason H. Moore, PhD, FACMI
Edward Rose Professor of Informatics,Director, Institute for Biomedical Informatics,Director, Division of Informatics,
Department of Biostatistics, Epidemiology, & Informatics,Senior Associate Dean for Informatics ,The Perelman School of Medicine University of Pennsylvania
Jason Moore is the Edward Rose Professor of Informatics and Director of the Penn Institute for Biomedical Informatics. He also serves as Senior Associate Dean for Informatics and Chief of the Division of Informatics in the Department of Biostatistics, Epidemiology, and Informatics. He came to Penn in 2015 from Dartmouth where he was Director of the Institute for Quantitative Biomedical Sciences. Prior to Dartmouth he served as Director of the Advanced Computing Center for Research and Education at Vanderbilt University where he launched their first high-performance computer. He has a Ph.D. in Human Genetics and an M.S. in Applied Statistics from the University of Michigan. He leads an active NIH-funded research program focused on the development of artificial intelligence and machine learning algorithms for the analysis of complex biomedical data. He is an elected fellow of the American Association for the Advancement of Science (AAAS), an elected fellow of the American College of Medical Informatics (ACMI), an elected fellow of the American Statistical Association (ASA), and was selected as a Kavli fellow of the National Academy of Sciences. He is currently Editor-in-Chief of the journal BioData Mining.
Erica Ramos, MS, LCGC.
President, National Society of Genetic Counselors and Dir & Head of Clinical Business Development at Geisinger National Precision Health
Erica Ramos, MS, LCGC is Director and Head of Clinical & Business Development at Geisinger National Precision Health, a program built on the innovations of Geisinger’s MyCode Community Health Initiative leveraging genomics and electronic health data. At Geisinger National, Ramos is focusing on the development and implementation of clinical strategic partnerships to extend the Geisinger model on the national scene and accelerate the transition from research to clinical programs, at Geisinger and beyond. She is also the 2018 President of the National Society of Genetic Counselors, the leading professional organization for genetic counselors more than 3500 members strong. Prior to joining Geisinger, Ms. Ramos spent 11 years in patient care, then joined Illumina’s Clinical Services Laboratory in 2012, where she managed the clinical group that implemented interpretation and reporting processes for clinical whole genome sequencing (cWGS). As an Associate Director of Market Development at Illumina, she then focused on advancing the use of whole genome sequencing in clinical care, with a focus on predictive genomics and population health. She also tweets from @ERamosSD about genomics and genetic counseling, music, travel and other interests.
David Roth, MD, PhD
Simon Flexner Professor and Chair of Pathology and Laboratory Medicine, Director, Penn Center for Precision Medicine, University of Pennsylvania Perelman School of Medicine
David B. Roth attended Rice University, obtained MD and PhD degrees from Baylor College of Medicine, and completed a residency in Anatomic Pathology at the National Cancer Institute. Roth joined the faculty of Baylor College of Medicine in 1993, and moved to New York University in 2001, where he served as Chair of the Department of Pathology and Director of the Medical Scientist Training Program. In 2011 Roth moved to the University of Pennsylvania as Chair of the Department of Pathology and Laboratory Medicine. At Penn, he founded the Center for Personalized Diagnostics, which was developed to bring genomic diagnostics to cancer patients. In 2016, he was named the Director of Penn’s new Center for Precision Medicine. His most recent research efforts are in applying principles of precision medicine to veterinary oncology, working with colleagues at Penn Vet.
Amy M. Miller, PhD
President & CEO, SWHR
Miller previously worked at the Personalized Medicine Coalition (PMC), where she served as Executive Vice President, working with innovators, scientists, providers and payers on scientific policy and business challenges impacting personalized medicine.
Before joining PMC, Miller worked in the office of the Director of the National Institute of Mental Health, where she served as a liaison among the scientific community, the legislative branch, and the consumers of mental health care and their families.
A former American Association for the Advancement of Science Fellow, Miller also served as a domestic policy advisor to Senator Jay Rockefeller. She began her career as a researcher at the National Institute of Child Health and Human Development.
Miller currently serves on the Editorial Board of Genome Magazine. She received a bachelor’s degree from the University of New Orleans and holds a doctoral degree in human development from the University of Connecticut.
Gary Palmer, MD
Chief Medical Officer, Tempus
Dr. Gary Palmer serves as Chief Medical Officer at Tempus, where he is responsible for leading clinical activities for the company and supporting external collaborations and strategic partnerships. Dr. Palmer most recently served as the Chief Medical Officer for NantHealth. Prior to his time there he served as Senior Vice President, Medical Affairs and Commercial Development at Foundation Medicine, where he helped launch the FoundationOne assay. Earlier in his career, Dr. Palmer served as the Chief of Medical Oncology at Mercy Health System, Sacramento and head of their Oncology Service Line. Prior to that he was as an Associate Professor of Medicine at University of California Davis Cancer Center. He earned a bachelor’s degree from Yale University, his medical degree from Stanford University School of Medicine and his masters of public health from the UCLA Fielding School of Public Health.
Holli Hutcheson Dilks, Ph.D.
Director of Personalized Medicine Operations, Sarah Canon Research Institute
Holli Hutcheson Dilks, Ph.D. joined Sarah Cannon in 2014 as the Director of Personalized Medicine Operations. In this role, she is responsible for providing scientific support and direction for the development and implementation of Sarah Cannon’s global Molecular Profiling/Personalized Medicine Initiative. Additionally, she is responsible for the development of biomarker strategies in support of disease area programs and individual clinical trials.
Prior to joining Sarah Cannon, Dilks served as Technical Director of the Vanderbilt Technologies for Advanced Genomics Core Resource and Director of Core Resources at the Center for Human Genetics Research at Vanderbilt University Medical Center. She also served as a faculty member at Lipscomb University College of Pharmacy and a Program Director for SRI International based in Washington, D.C. Dilks received her B.A. from Lipscomb University, her Ph.D. in Molecular Physiology and Biophysics from Vanderbilt University, and performed her postdoctoral Cancer Research Training Award fellowship at the National Cancer Institute (NIH). During her fellowship, she served as a visiting scientist at the Broad Institute of MIT and Harvard. In addition to her role at Sarah Cannon, Dilks currently serves as an Adjunct Assistant Professor for the Department of Pharmaceutical Sciences at Lipscomb University College of Pharmacy.
Timothy A. Chan, MD, PhD
PaineWebber Chair in Cancer Genetics; Director, Immunogenomics and Precision Oncology Platform; Member, Human Oncology & Pathogenesis Program; Vice Chair, Department of Radiation Oncology; Director, Translational Oncology Division
I am Vice Chair of the Department of Radiation Oncology and Director of the Division of Translational Oncology. I am a board-certified radiation oncologist with a special interest in treating patients with brain tumors. I specialize in the use of stereotactic radiosurgery, intensity-modulated radiation therapy (IMRT), and conformal radiation therapy to treat both benign and malignant brain tumors precisely and effectively, while minimizing the effects of treatment on nearby healthy tissue. Among the diseases I treat are acoustic neuroma, meningioma, glioblastoma, anaplastic astrocytoma, low-grade glioma, oligodendroglioma, pituitary adenoma, and ependymoma.
I am a member of Memorial Sloan Kettering’s central nervous system disease management team, and I work closely with neurosurgeons and neuro-oncologists to provide optimal care for our patients. I am also a member of the Brain Tumor Center.
In addition to caring for patients, I am the principal investigator of a cancer genetics laboratory in the Human Oncology and Pathogenesis Program, where my colleagues and I are exploring the genetic changes that lead to cancer. We are dedicated to using our findings on the cancer genome to develop better diagnostic and treatment approaches that will improve the care of people with cancer.
Nicholas Dracopoli, PhD
Dr. Klempner is a medical oncologist with a focus in gastrointestinal malignancies, oncogene driven tumors and clinical trials. His clinical and translational research is focused on cancer genomics, acquired resistance to targeted therapies and the intersection of genomics and immune mediated therapies to identify novel therapeutic approaches.
Dr. Klempner completed his residency in internal medicine at Brigham and Women’s Hospital/Harvard Medical School, followed by a combined hematology-oncology fellowship at Beth Israel Deaconess Medical Center/Harvard Medical School. While at Harvard Dr. Klempner studied the mechanisms of resistance to targeted therapies in tumor cells in the lab of Dr. Lewis Cantley, PhD. Dr. Klempner is board certified in medical oncology, hematology, and internal medicine. Prior to joining The Angeles Clinic and Research Institute Dr. Klempner served as an Assistant Clinical Professor in the division of Hematology-Oncology at the University of California Irvine. His research has been presented at major international meetings including the American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), the American Association for Cancer Research (AACR), and published in journals including the Journal of Clinical Oncology (JCO), Cancer Discovery, JAMA Oncology, Annals of Oncology and others. A complete list of publications can be found here.
Currently Dr. Klempner serves as the Director of Precision Medicine and GI Oncology at The Angeles Clinic and Research Institute. His ongoing research projects are focused in gastroesophageal malignancies.
Outside of the clinic Dr. Klempner enjoys woodworking, traveling with his wife, exercise, hunting, and spending time outside.
Arturo Loaiza-Bonilla, MD, MSEd, FACP
Vice Chair, CTCA Department of Medical Oncology, CTCA Philadelphia
Dr. Arturo Loaiza-Bonilla is the current Vice Chair of Medical Oncology of Research at Cancer Treatment Centers of America – ERMC, and also Co-Founder and Chief Medical Officer at Massive Bio (www.massivebio.com). A precision oncology expert with experience at the Abramson Cancer Center of the University of Pennsylvania, University of Miami, Johns Hopkins and the National Institutes of Health, his major interest focuses in the field of innovative approaches to match oncology patients to phase 1-3 clinical and translational research cancer trials, integrating next-generation personalized molecular diagnostics, immunotherapy, biomarkers, previous therapies, and the patient’s overall status under an Artificial Intelligence-based and machine learning platform, which integrates to the electronic medical record. His company and virtual tumor board / clinical trial matching platforms have been recently featured in GenomeWeb and MedPage Today, including a first-in-the-world registry, SYNERGY-AI to match cancer patients based on Artificial Intelligence (https://clinicaltrials.gov/ct2/show/NCT03452774)
Dr. Loaiza-Bonilla is Principal and co-investigator on several Phase I/III clinical trials in several malignancies at Cancer Treatment Centers of America, with emphasis in new targeted therapies, novel molecules and immunotherapy, tailored to specific tumor type, its genomics and protein expression profiles. He is also a passionate advocate for improved access to medical care, precision oncology, medical education, organized medicine leadership and health policy, having been awarded the ‘Top 40 Under 40’ award by the Philadelphia Business Journal, AMA Foundation Leadership Award, Fellowship of the American College of Physicians, and holding a Master in Medical Education (M.S.Ed) degree from the University of Pennsylvania. He has held several leadership positions in state and medical societies, including his current tenure as executive board member of the Pennsylvania Society of Oncology and Hematology, and his role as President of the Board of Directors of the Global Alliance for Patient Access.
Eric B Kmiec Ph.D.
Director, Gene Editing Program,Senior Research Scientist, Center for Translational Cancer Research, Helen F. Graham Cancer Center and Research Institute
Eric B. Kmiec, Ph.D., is well-known for his pioneering work in the fields of molecular medicine and gene editing. Throughout his professional career, Dr. Kmiec has led research teams in developing gene editing technologies and genetic therapies for inherited disorders such as Sickle Cell Disease. He is the recipient of multiple research awards from the National Institutes of Health (RO1s, R21s), the American Cancer Society, and private foundations including the 2012 Proudford Foundation Unsung Hero Award in Sickle Cell Disease. He has been a member of numerous editorial boards, NIH study sections and review boards and is the (primary/senior) author of more than 145 scientific publications (mostly in genetic recombination and gene editing).
He holds 18 issued patents, most of which have been licensed by biotechnology and pharmaceutical companies and has founded two biotechnology companies. He is a senior scientific advisor and SAB member of ETAGEN, a gene editing company located in Cambridge, Massachusetts, centered on the development of therapeutic uses of gene editing. Dr. Kmiec has been the primary mentor for 18 Ph.D. students and 4 MS students, all of whom have attained scientific positons. He has held or holds major administrative posts in various on NIH regional and state biomedical research grants, including IDeA Network of Biomedical Research (INBRE) and Centers of Biomedical Research Excellence (COBRE). Dr. Kmiec was also honored as the Eminent Scholar in residence at Marshall University (Huntington, West Virginia) in 2009-2011 and was elected as an Honorary Commander of the 436th Air Wing at Dover Air Force Base in Dover, Delaware for in 2013 and again in 2014.
The Gene Editing Institute, founded by Dr. Kmiec, is a core facility providing genetic tools for gene editing as well as instruction in the design and implementation of these tools for collaborators and colleagues nationwide. Currently, the Institute is working with a variety of groups within the Delaware/ IDeA state network and has recently developed an educational module for instruction of gene editing in undergraduate teaching laboratories. This module will be licensed, marketed and sold through an international biotechnology company.
Stephanie Devaney, Ph.D.
Deputy Director – All of Us Research Program, National Institutes of Health.
Stephanie Devaney is the Deputy Director of the All of Us Research Program at the National Institutes of Health. Prior to this she led the coordination of the Precision Medicine Initiative from the Office of the Chief of Staff at the White House. In this role she coordinated the many components of the Initiative and guided the vision of the overall effort, along with the many federal partners. Before joining the White House, Stephane worked in the Office of the Director at the National Institutes of Health. There she helped advance policies critical to biomedical research and the NIH mission and assisted in the development of programs and research initiatives to advance national scientific priorities, including the Precision Medicine Initiative. Prior to that, Stephanie was a researcher at the Genetics and Public Policy Center at Johns Hopkins University. There she conducted research on pharmacogenetics and drug labeling; performed a meta-analysis of non-invasive fetal gender genetic testing; and was involved in public engagement surrounding the many ethical and social issues that are emerging with novel genomic technologies. Stephanie received her Ph.D. in Molecular Genetics from the George Washington University and her B.S. in Biology from The Ohio State University.
Richard D. Hammer, M.D.
Vice-Chair of Clinical Affairs, Department of Pathology & Anatomical Sciences, University of Missouri School of Medicine
Dr. Richard D. Hammer completed his undergraduate degree in Pharmacy from Duquesne University in Pittsburgh Pa., graduating Magna Cum Laude. While in Pharmacy school he gained experience in research in Medicinal Chemistry. He then was admitted to the elite combined M.D./Ph.D at the Medical University of South Carolina in Charleston, SC. where he studied pharmacology and the biochemistry of drug metabolism. He received his medical degree from the Medical University of South Carolina in Charleston, SC graduating in the top 10 in his class of 145. He then completed a 5 year-residency in Anatomic and Clinical Pathology at Vanderbilt University in Nashville TN. This was followed by a specialty year in Surgical Pathology and Cytology and then a two-year
fellowship in Hematopathology under Dr. Robert Collins, codeveloper of the Lukes-Collins lymphoma classification system. Dr. Hammer also spent an additional year of fellowship training in molecular pathology techniques with Dr. Cindy Vnencak-Jones at Vanderbilt developing novel molecular assays related to lymphomas. During his hematopathology training, Dr. Hammer was recipient of National Institute of Health training grant for three consecutive years with numerous publications, including defining papers describing splenic marginal zone lymphomas, immunocytochemistry of acute leukemias, cyclin D1, and NK/T cell leukemias. Dr. Hammer is board certified in Anatomic and Clinical Pathology with subspecialty board certification in Hematology.
Dr. Hammer is currently Vice Chair of Pathology and Anatomical Sciences at the University of Missouri. He is also Director of Hematopathology and Coagulation and Core Faculty at the MU Informatics Institute which has one of the largest graduate programs in medical informatics in the country. His research interests are in hematopathology, clinical decision support, translational bioinformatics and diagnostics, and imaging.
On a personal note, Dr. Hammer is an International referee in the World Drug Free Powerlifting Federation and holds the state record in Missouri for powerlifting. He also enjoys running and hiking and recently completed his first ultramarathon.
Tara Schmidlen, MS, CGC
Clinical Investigator / Genetic Counselor – Geisinger Health System
Tara Schmidlen is a research genetic counselor with 12 years of experience in providing telephone-based genetic counseling for adult onset complex disease and pharmacogenomics, research biobanking and precision health research. She earned her Bachelor of Science degree in Biobehavioral Health from The Pennsylvania State University in 2002 and her Master of Science degree in Genetic Counseling from Arcadia University in 2006. She joined Geisinger in 2017 as a Clinical Investigator to further explore her research interests which center around the development of alternative genetic counseling service delivery models- particularly those that leverage the use of technology to facilitate communication with patients.
Andrey Antov, PhD, MBA
Program Director, Maine Cancer Genomics Initiative, The Jackson Laboratory
Andrey is the Program Director for the MCGI. His healthcare professional experience includes basic research, medical device contracting and pharmaceutical; he has held a number of different roles from administration to consulting. Andrey holds a Ph.D in immunobiology and an M.B.A. in marketing and strategy from Yale University as well as a M.Sc. in biochemistry and a M.SC in ecology from The Sofia University in Bulgaria.
The Maine Cancer Genomics Initiative (MCGI) is the first-of-its-kind community-based genomic medicine program in Maine. Its goal is to deliver the very best precision cancer treatment across the entire state and further connect regional care centers with urban clinical trials for the best patient outcomes. The Initiative will cover the cost of genomic sequencing for 1,800 patients. Under the leadership of The Jackson Laboratory, patients at all Maine cancer practices are benefitting from the project. MCGI is filling the gap between innovation and implementation, providing education to clinicians and patients and, most importantly, making genomic testing accessible so that it can be adopted as a regular practice for Maine patients with cancers of varying complexity. https://www.jax.org/clinical-genomics/maine-cancer-genomics-initiative
Charlene Son Rigby, MBA
Chief Business Officer, Fabric Genomics
Charlene Son Rigby is responsible for customer success, business development and regulatory at Fabric Genomics. Charlene has spent her career building businesses at the intersection of data, technology and life sciences. Previous to Fabric Genomics, she was responsible for all go-to-market activities at Metamarkets, a big data analytics startup acquired by Snap. Charlene was also Vice President of Business Planning at Oracle. She also led product management at DoubleTwist, a bioinformatics startup. Charlene started her career as a neuroscience researcher at Syntex (acquired by Roche). She holds a B.A. in Human Biology from Stanford University and an M.B.A. from the Haas School of Business at U.C. Berkeley.
Ilan “Lanny” Kirsch, M.D.
Senior Vice President of Translational Medicine, Adaptive Biotechnologies
Dr. Kirsch received his M.D. from Harvard University Medical School and subsequently completed his Residency at Children’s Hospital Medical Center, Boston, Massachusetts and his Fellowship in Pediatric Hematology/Oncology at the National Cancer Institute (NCI) in Bethesda, Maryland. Dr. Kirsch also completed a three-year postdoctoral fellowship in molecular genetics in the laboratory of Dr. Philip Leder at the National Institute of Child Health and Human Development. Subsequently Dr. Kirsch spent over 20 years at the NCI as a basic researcher, attending physician, and, ultimately, Chief of the Genetics Branch within the Center for Cancer Research. In 2005 Dr. Kirsch joined the biotech/pharma company, Amgen, as an Executive Director heading the Oncology Research group at Amgen Washington in Seattle. During the next six years the Amgen Washington group was responsible for bringing a number of different therapeutic targets and modalities to Phase 1 trial evaluation. He currently serves as the Senior Vice President of Translational Medicine, Adaptive Biotechnologies, Seattle, Washington (www.adaptivebiotech.com). Adaptive Biotechnologies, a spin-out from the Fred Hutchinson Cancer Research Center, has developed a state-of-the-art platform of immunosequencing for the enumeration, specification, and quantification of each and every T- and/or B-cell in any sample of interest. Dr Kirsch is an author of more than 150 peer-reviewed manuscripts and over 30 books, chapters, or reviews.
David B. Nash, MD, MBA
Dean Jefferson College of Population Health, Dr. Raymond C. & Doris N. Grandon Professor of Health Policy
Selin Kurnaz, Ph.D.
CEO – Massive Bio
Dr. Kurnaz is an expert in strategy, operations and transactions with a unique, global background that spans across healthcare, academia and consulting. After completing a PhD at the University of Michigan and receiving multiple engineering degrees, Dr. Kurnaz spent more than a decade delivering revenue enhancement, margin optimization and capital efficiency improvements for Pharmaceutical and Life Science companies. Dr. Kurnaz also has measurable success identifying and delivering value to over a dozen investment firms. Most recently, Dr. Kurnaz was with EY’s Private Equity Value Creation. Dr. Kurnaz has also written and spoke extensively about improving customer responsiveness in disruptive times.
Severence MacLaughlin, PhD
Chief of Intelligence, VP – Artificial Intelligence and Data Sciences, Capgemini Invent
Severence serves as the Chief of Intelligence, Vice President – Artificial Intelligence & Data Scicences, of Capgemini Invent. Dr. MacLaughlin oversees and develops the sales, solutions and delivery of Systems of Intelligence that address complex corporate/organizational opportunities driving increased productivity, financial ROI as well as enhanced regulatory compliance in the verticals of Healthcare, Life Sciences, Banking & Financial Services, Oil &Gas, Natural Resources as well as Entertainment, Retail and Consumer Packaged Goods.
Dr. MacLaughlin is a thought leader in the application of Artificial Intelligence, Data Sciences & Advanced Analytics space and has helped numerous Healthcare (Payer, Provider, Technology & Government), Life Sciences (Pharma, Biotech & Medical Device) and Financial Services (Investment Banks, Hedge Funds, Private Equity and Venture Capital firms) organizations in addressing complex business challenges, resulting in improved health outcomes, better operational efficiencies, enhanced regulatory compliance, decreased costs and increased top line growth in an entrepreneurial fashion. He is well versed in Pharma operations from
development, clinical trials to regulatory and go to market events. In the Healthcare space, Severence is seen as a trusted advisor to the CXO’s in aiding digitization of Medical Operations for Hospitals and Providers as well as increasing health outcomes for the Payer Community.
Dr. MacLaughlin is one of the top ranked Life Sciences/Healthcare Data Scientists globally (Ranked among top 20 Life Sciences Data Scientists; Ranked #2 Healthcare Data Scientist; Ranked #1 Consulting Data Scientist in the Life Sciences and Healthcare knowledge base; Recognized as American Healthcare Leader for Q1 2018). Severence M. MacLaughlin’s career is comprised of a demonstrated track record in Artificial Intelligence, Data Sciences, Operational Strategic Analytics, BioIntelligence, Competitive Intelligence, Due Diligence and Project Execution for Healthcare, Life Science and Financial Services industries. Severence’s experiences encompass advising members of domestic and foreign governments on policy development for Technology Development (Artificial Intelligence), Healthcare, Life Sciences & Education (USA, UK, France, Australia, Russia & Kingdom of Denmark). In addition to these areas of expertise, Dr. MacLaughlin has interests in helping executive’s across a broad range of business sectors harness the true potential of their internal data sets to improve operational efficiency, rationalize costs and increase top line growth.
Severence has advised a diverse number of industries ranging from insurance, financial services, US auto sales, franchise based businesses, agriculture, academic institutions, and other Fortune 500 companies. Dr. Severence’s clients include advising the C suite of the top 25 global Health Care Insurance and Hospital Groups, the top 20 Pharma companies and two of the top Global Investment Banks. Severence manages the go-to-market, sales, solutioning and delivery of novel AI and data science accelerators in addition to advising and consulting executive integration and formulation of Data Sciences and Big Data Strategy Roadmap for these organizations. Dr. MacLaughlin has delivered over 40 new disruptive technologies and or implemented Systems of Intelligence resulting in over $1.8B in net present value to customers and an estimated $8B ROI over the next five years. In addition, Severence evaluates potential companies and technologies for acquisition and has developed a robust System for M&A and corporate restructuring activities encompassed within Due Diligence through Data Integrity (DDDI)
resulting in an increased rate of return on investment (RROI) & an improved process efficiency.
Prior to Capgemini Invent, Severence was the Global Head for Artificial Intelligence & Data Sciences in the Healthcare & Life Sciences verticals and Head, Artificial Intelligence Learning Institute (AILI) and Cognizant Academy of Data Sciences (CADS) at Cognizant Technology Solutions. Before his time at Cognizant, Dr. MacLaughlin served as Managing Director at MGI&I, where he brought to bear the power of data sciences and advanced analytics fortelecom, automotive, healthcare, pharma and financial service clients (VC, PE, Hedge Funds) in terms of operational improvements, mergers & acquisitions and corporate restructuring.
Severence earned a BS (Magna Cum Laude, Honors & Distinction in Research) at Cornell University, a Doctorate Degree (Honors, Top 1%) from the University of Adelaide and a postdoctoral fellowship at the University of South Australia, where he maintains an adjunct academic position and taught medical, dental and nursing curricula. Severence has authored over 20 international scientific papers and given invited lectures and conference papers at academic
institutions as well as international scientific events. Severence is personally interested in equine, bovine and ovine genetics and breeding as well as being an accomplished equestrian and amateur polo player.
Yves Lussier, MD, FACMI
Associate Vice President for Health Sciences and Chief Knowledge Officer, Executive Director, Center for Biomedical Informatics and Biostatistics, University of Arizona Health Sciences
Dr. Lussier is the Associate Vice President for Information Science and Chief Knowledge Officer of the UA Arizona Health Sciences (UAHS), Founding Director of the Center for Biomedical Informatics and Biostatistics, and Professor of Medicine. He received a bachelor of engineering and his medical degree from the University of Sherbrooke, Quebec, Canada. He performed predoctoral research in the Departments of Medicine and Human Physiology at the University of Sherbrooke and then completed an internship in ophthalmology at Laval University Hospital in Quebec City, and a residency in family medicine at the University of Sherbrooke Medical Center. He was a post-doctoral residential fellow in the Department of Biomedical Informatics in the College of Surgeons & Physicians at Columbia University. Dr. Lussier’s research group conducts pioneering hypothesis-driven computational modeling predictions in precision medicine that are then validated in vitro, in vivo and in clinical trials. As a leader of the fields of translational bioinformatics and of Data Science-augmented precision medicine, he has launched successful companies and international conferences, authored 185 publications, and delivered more than 100 invited presentations in precision medicine, systems medicine, and translational bioinformatics, including 21 opening keynotes at international conferences. He has been awarded $190,000,000 in grants as principal, core leader, or co-investigator, and mentored 53 graduate and postgraduate students as well as 40 junior faculty members. Dr. Lussier’s honors include three IBM Faculty Awards, inducted Fellow of the American College of Medical Informatics (ACMI), 1st recipient of the Columbia University Faculty Mentoring Award, “Ambassador for Health Sciences” at the University of Sherbrooke (Canada), and 16 outstanding publication awards from the American Medical Informatics Association (AMIA), the International Society for Computational Biology (ISCB), and the Translational Bioinformatics Conference (TBC). In 2016, Dr. Lussier was invited among ten USA academic leaders invited by the White House for its Precision Medicine Summit, where the University of Arizona Center for Biomedical Informatics and Biostatistics that he directs has committed $20M of R&D in bringing precision medicine to practice.
Lorenz M. Mayr, Ph.D.
Chief Technology Officer (CTO), GE Healthcare Life Sciences
Since May 2017, Lorenz has been the Chief Technology Officer (CTO) for GE Healthcare Life Sciences and is responsible for all R&D investments, research programs, business growth strategy, technology innovation, and R&D talent development across all business areas (BioProcess, Imaging Diagnostics/Contrast Media, Research Tools and Applied Markets, Cell & Gene Therapy, New Opportunities).
Previously, he had been the Vice President & Global Head, Reagents & Assay Development with responsibility for generation of all biological reagents and assay development activities across all therapeutic research areas at AstraZeneca.
Before that, he was Executive Director at Novartis Pharma in Basel/Switzerland, at Bayer Pharma Research in Wuppertal/Germany, at Bayer Central Research in Leverkusen/Germany and at the M.I.T./Whitehead Institute in Cambridge/ Massachusetts (U.S.A.). He is lecturer for Biochemistry at the Martin-Luther University in Halle/Saale (Germany), has published over 60 papers in peer-reviewed journals and is member of several Scientific Advisory Boards (SABs).
He has received degrees in biochemistry, biophysics, molecular & cell biology at the University of Tubingen (Germany), University of Bayreuth (Germany) and the University of Colorado at Boulder (U.S.A.).
Smilow Center for Translational Research
3400 Civic Center Boulevard
Philadelphia, Pennsylvania 19104
There are numerous options for accommodation while attending the event. Please utilize your regular resources for travel and accommodation. The Precision Medicine Leaders’ Summit, Kneed Media, or the University of Pennsylvania do not engage with any third parties to provide assistance for accommodation or travel.
As you are probably aware there are numerous entities that may approach you to book your travel and accommodation, please ignore these solicitations as they are in no way associated with the Precision Medicine Leaders’ Summits.
There is limited parking available at the event venue.